Trials / Terminated
TerminatedNCT00241345
Trial of Preemptive Treatment With Oral Valganciclovir Compared With Intravenous (IV) Ganciclovir for Cytomegalovirus Infection After Bone Marrow or Peripheral Blood Stem Cell Transplant
Randomized Trial of Preemptive Treatment With Oral Valganciclovir Compared With IV Ganciclovir for Cytomegalovirus Infection After Bone Marrow or Peripheral Blood Stem Cell Transplant
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- Washington University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to determine if preemptive therapy with oral valganciclovir is as effective as intravenous ganciclovir in clearing cytomegalovirus (CMV) viremia as determined by quantitative CMV polymerase chain reaction (PCR) assay in patients who have undergone bone marrow or peripheral blood stem cell transplant.
Detailed description
* To study the effect of preemptive therapy with IV ganciclovir and PO valganciclovir as determined by quantitative CMV PCR. * To determine the incidence of CMV disease and CMV related mortality following preemptive treatment with oral valganciclovir and IV ganciclovir. * To compare the incidence of recurrent CMV viremia after treatment with PO valganciclovir to that seen after treatment with IV ganciclovir. * To determine the toxicity profile of valganciclovir. * To screen for mutations in the UL97 gene in patients who have increasing CMV viral loads after 14 days of treatment. * To determine if patients treated with PO valganciclovir have ganciclovir drug levels which are equivalent to those seen in historical control subjects treated with PO valganciclovir.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Valganciclovir | |
| DRUG | Ganciclovir |
Timeline
- Start date
- 2004-06-01
- Primary completion
- 2007-11-01
- Completion
- 2007-12-01
- First posted
- 2005-10-18
- Last updated
- 2013-07-23
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00241345. Inclusion in this directory is not an endorsement.